Biodesix Inc
BDSX6.690USD
-0.410-5.77%
Close 12/19, 16:00（ET）Quotes delayed by 15 min
53.22MMarket Cap
LossP/E TTM
More Details of Biodesix Inc Company
Biodesix, Inc. is a diagnostic solutions company. Biodesix Diagnostic Tests, marketed as Nodify Lung Nodule Risk Assessment and IQLung Cancer Treatment Guidance, support clinical decisions to expedite personalized care and improve outcomes for patients with lung disease. Biodesix Development Services enable biopharmaceutical, life sciences, and research institutions with scientific, technological, and operational capabilities that fuel the development of diagnostic tests, tools, and therapeutics. The Nodify Lung Nodule Risk Assessment assesses a suspicious lung nodule's risk of lung cancer to help identify the most appropriate treatment pathway. Nodify CDT and Nodify XL2 tests are marketed as Nodify Lung Nodule Risk Assessment. The Nodify CDT test is a blood-based test that detects the presence of seven autoantibodies associated with the presence of tumors. GeneStrat ddPCR, GeneStrat NGS and VeriStrat tests are marketed as part of its IQLung testing strategy.
Biodesix Inc Info
Ticker SymbolBDSX
Company nameBiodesix Inc
IPO dateOct 28, 2020
CEOHutton (Scott)
Number of employees273
Security typeOrdinary Share
Fiscal year-endOct 28
Address919 West Dillon Road
CityLOUISVILLE
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code80027
Phone13034170500
Websitehttps://www.biodesix.com/
Ticker SymbolBDSX
IPO dateOct 28, 2020
CEOHutton (Scott)
Company Executives of Biodesix Inc
Name
Name/Position
Position
Shareholding
Change
Mr. John Patience
Mr. John Patience
Independent Chairman of the Board
Independent Chairman of the Board
373.31K
+0.31%
Dr. Matthew W. Strobeck, Ph.D.
Dr. Matthew W. Strobeck, Ph.D.
Independent Director
Independent Director
152.98K
--
Mr. Hany Massarany
Mr. Hany Massarany
Independent Director
Independent Director
18.18K
+7.82%
Dr. Jon Faiz Kayyem, Ph.D.
Dr. Jon Faiz Kayyem, Ph.D.
Independent Director
Independent Director
17.88K
--
Ms. Robin Harper Cowie
Ms. Robin Harper Cowie
Chief Financial Officer, Treasurer, Secretary
Chief Financial Officer, Treasurer, Secretary
12.65K
+0.86%
Mr. Kieran O'Kane
Mr. Kieran O'Kane
Chief Commercial Officer
Chief Commercial Officer
7.05K
+0.71%
Ms. Jean M. Franchi, CPA
Ms. Jean M. Franchi, CPA
Independent Director
Independent Director
5.41K
+32.23%
Mr. Lawrence T. (Lair) Kennedy, Jr.
Mr. Lawrence T. (Lair) Kennedy, Jr.
Independent Director
Independent Director
--
--
Mr. Scott Hutton
Mr. Scott Hutton
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. John Patience
Mr. John Patience
Independent Chairman of the Board
Independent Chairman of the Board
373.31K
+0.31%
Dr. Matthew W. Strobeck, Ph.D.
Dr. Matthew W. Strobeck, Ph.D.
Independent Director
Independent Director
152.98K
--
Mr. Hany Massarany
Mr. Hany Massarany
Independent Director
Independent Director
18.18K
+7.82%
Dr. Jon Faiz Kayyem, Ph.D.
Dr. Jon Faiz Kayyem, Ph.D.
Independent Director
Independent Director
17.88K
--
Ms. Robin Harper Cowie
Ms. Robin Harper Cowie
Chief Financial Officer, Treasurer, Secretary
Chief Financial Officer, Treasurer, Secretary
12.65K
+0.86%
Mr. Kieran O'Kane
Mr. Kieran O'Kane
Chief Commercial Officer
Chief Commercial Officer
7.05K
+0.71%
Revenue Breakdown
Currency: USDUpdated: Mon, Oct 6
Currency: USDUpdated: Mon, Oct 6
FY2025Q2
FY2025Q1
FY2024
By BusinessUSD
Name
Revenue
Proportion
Lung Diagnostic Testing
17.90M
89.41%
Development Services
2.12M
10.59%
Relevant data have not been disclosed by the company yet.
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
Lung Diagnostic Testing
17.90M
89.41%
Development Services
2.12M
10.59%
Shareholding Stats
Updated: Wed, Oct 29
Updated: Wed, Oct 29
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Schuler (Jack W)
26.78%
Kennedy (Lawrence T Jr.)
16.00%
Telemark Asset Management, LLC
5.21%
Patience (John)
4.69%
Birchview Capital, LP
3.60%
Other
43.72%
Shareholders
Shareholders
Proportion
Schuler (Jack W)
26.78%
Kennedy (Lawrence T Jr.)
16.00%
Telemark Asset Management, LLC
5.21%
Patience (John)
4.69%
Birchview Capital, LP
3.60%
Other
43.72%
Shareholder Types
Shareholders
Proportion
Individual Investor
51.00%
Investment Advisor
12.29%
Hedge Fund
3.40%
Corporation
1.37%
Private Equity
1.37%
Investment Advisor/Hedge Fund
0.91%
Research Firm
0.11%
Other
29.55%
Institutional Shareholding
Updated: Mon, Dec 8
Updated: Mon, Dec 8
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
106
1.44M
36.52%
--
2025Q3
107
1.45M
36.66%
-344.58K
2025Q2
107
1.79M
45.09%
-888.44K
2025Q1
105
2.68M
48.65%
-880.49K
2024Q4
100
2.95M
44.33%
-176.20K
2024Q3
93
3.13M
37.31%
+438.60K
2024Q2
96
2.69M
15.79%
+1.57M
2024Q1
114
820.05K
16.77%
+5.46K
2023Q4
112
794.09K
17.61%
-6.06K
2023Q3
117
800.27K
19.08%
+20.36K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Schuler (Jack W)
2.13M
29.06%
+160.42K
+8.14%
Sep 19, 2025
Kennedy (Lawrence T Jr.)
1.27M
17.36%
+5.31K
+0.42%
Mar 03, 2025
Telemark Asset Management, LLC
414.13K
5.65%
--
--
Jun 30, 2025
Patience (John)
373.31K
5.09%
+1.14K
+0.31%
Sep 30, 2025
Birchview Capital, LP
286.81K
3.91%
--
--
Jun 30, 2025
The Vanguard Group, Inc.
189.67K
2.59%
-1.52K
-0.79%
Jun 30, 2025
Strobeck (Matthew W)
152.98K
2.09%
--
--
Mar 03, 2025
Perceptive Advisors LLC
108.69K
1.48%
--
--
Jun 30, 2025
Monashee Investment Management, LLC
100.00K
1.36%
-102.50K
-50.62%
Jun 30, 2025
Industrial Development Funding LLC
94.39K
1.29%
+94.39K
--
Sep 30, 2024
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
iShares Micro-Cap ETF
0%
iShares Micro-Cap ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Sep 11, 2025
Merger
20→1
Date
Type
Ratio
Sep 11, 2025
Merger
20→1
FAQs
Who are the top five shareholders of Biodesix Inc?
The top five shareholders of Biodesix Inc are:
Schuler (Jack W) holds 2.13M shares, accounting for 29.06% of the total shares.
Kennedy (Lawrence T Jr.) holds 1.27M shares, accounting for 17.36% of the total shares.
Telemark Asset Management, LLC holds 414.13K shares, accounting for 5.65% of the total shares.
Patience (John) holds 373.31K shares, accounting for 5.09% of the total shares.
Birchview Capital, LP holds 286.81K shares, accounting for 3.91% of the total shares.
Schuler (Jack W) holds 2.13M shares, accounting for 29.06% of the total shares.
Kennedy (Lawrence T Jr.) holds 1.27M shares, accounting for 17.36% of the total shares.
Telemark Asset Management, LLC holds 414.13K shares, accounting for 5.65% of the total shares.
Patience (John) holds 373.31K shares, accounting for 5.09% of the total shares.
Birchview Capital, LP holds 286.81K shares, accounting for 3.91% of the total shares.
What are the top three shareholder types of Biodesix Inc?
The top three shareholder types of Biodesix Inc are:
Schuler (Jack W)
Kennedy (Lawrence T Jr.)
Telemark Asset Management, LLC
Schuler (Jack W)
Kennedy (Lawrence T Jr.)
Telemark Asset Management, LLC
How many institutions hold shares of Biodesix Inc (BDSX)?
As of 2025Q4, 106 institutions hold shares of Biodesix Inc, with a combined market value of approximately 1.44M, accounting for 36.52% of the total shares. Compared to 2025Q3, institutional shareholding has increased by -0.13%.
What is the biggest source of revenue for Biodesix Inc?
In FY2025Q2, the Lung Diagnostic Testing business generated the highest revenue for Biodesix Inc, amounting to 17.90M and accounting for 89.41% of total revenue.
